296 related articles for article (PubMed ID: 30593782)
1. Nanoparticle encapsulation increases the brain penetrance and duration of action of intranasal oxytocin.
Oppong-Damoah A; Zaman RU; D'Souza MJ; Murnane KS
Horm Behav; 2019 Feb; 108():20-29. PubMed ID: 30593782
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin.
Zaman RU; Mulla NS; Braz Gomes K; D'Souza C; Murnane KS; D'Souza MJ
Int J Pharm; 2018 Sep; 548(1):698-706. PubMed ID: 30031864
[TBL] [Abstract][Full Text] [Related]
3. Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Alam MA; Ahmad FJ
Drug Res (Stuttg); 2018 Oct; 68(10):584-595. PubMed ID: 29669380
[TBL] [Abstract][Full Text] [Related]
4. Evidence for intranasal oxytocin delivery to the brain: recent advances and future perspectives.
Quintana DS; Smerud KT; Andreassen OA; Djupesland PG
Ther Deliv; 2018 Jul; 9(7):515-525. PubMed ID: 29943688
[TBL] [Abstract][Full Text] [Related]
5. Emerging trends in the delivery of nanoformulated oxytocin across Blood-Brain barrier.
Al-Suhaimi EA; Nawaz M; Khan FA; Aljafary MA; Baykal A; Homeida AM
Int J Pharm; 2021 Nov; 609():121141. PubMed ID: 34597727
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-mediated delivery of neurotoxin-II to the brain with intranasal administration: an effective strategy to improve antinociceptive activity of neurotoxin.
Ruan Y; Yao L; Zhang B; Zhang S; Guo J
Drug Dev Ind Pharm; 2012 Jan; 38(1):123-8. PubMed ID: 21721852
[TBL] [Abstract][Full Text] [Related]
7. Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study.
Qureshi M; Aqil M; Imam SS; Ahad A; Sultana Y
Curr Drug Deliv; 2019; 16(2):123-135. PubMed ID: 30317997
[TBL] [Abstract][Full Text] [Related]
8. Influence of PLA-PEG nanoparticles manufacturing process on intestinal transporter PepT1 targeting and oxytocin transport.
Gourdon B; Chemin C; Moreau A; Arnauld T; Delbos JM; Péan JM; Declèves X
Eur J Pharm Biopharm; 2018 Aug; 129():122-133. PubMed ID: 29803721
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
10. Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
Shah B; Khunt D; Misra M; Padh H
Pharm Res; 2018 Jan; 35(1):8. PubMed ID: 29294189
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of Brain Bioavailability Using Thermoreversible Cubosomal Formulation.
Jain H; Prabhakar B; Shende PK
Mol Pharm; 2024 May; 21(5):2534-2543. PubMed ID: 38547474
[TBL] [Abstract][Full Text] [Related]
12. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease.
Muntimadugu E; Dhommati R; Jain A; Challa VG; Shaheen M; Khan W
Eur J Pharm Sci; 2016 Sep; 92():224-34. PubMed ID: 27185298
[TBL] [Abstract][Full Text] [Related]
13. Double or Simple Emulsion Process to Encapsulate Hydrophilic Oxytocin Peptide in PLA-PEG Nanoparticles.
Gourdon B; Declèves X; Péan JM; Chemin C
Pharm Res; 2018 Mar; 35(4):82. PubMed ID: 29508092
[TBL] [Abstract][Full Text] [Related]
14. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
[TBL] [Abstract][Full Text] [Related]
15. CSF and blood oxytocin concentration changes following intranasal delivery in macaque.
Dal Monte O; Noble PL; Turchi J; Cummins A; Averbeck BB
PLoS One; 2014; 9(8):e103677. PubMed ID: 25133536
[TBL] [Abstract][Full Text] [Related]
16. Intranasal oxytocin effects on social cognition: a critique.
Evans SL; Dal Monte O; Noble P; Averbeck BB
Brain Res; 2014 Sep; 1580():69-77. PubMed ID: 24239931
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive evaluation of chitosan nanoparticle based phage lysin delivery system; a novel approach to counter S. pneumoniae infections.
Gondil VS; Dube T; Panda JJ; Yennamalli RM; Harjai K; Chhibber S
Int J Pharm; 2020 Jan; 573():118850. PubMed ID: 31759993
[TBL] [Abstract][Full Text] [Related]
18. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans.
Striepens N; Kendrick KM; Hanking V; Landgraf R; Wüllner U; Maier W; Hurlemann R
Sci Rep; 2013 Dec; 3():3440. PubMed ID: 24310737
[TBL] [Abstract][Full Text] [Related]
19. Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery.
Hao J; Zhao J; Zhang S; Tong T; Zhuang Q; Jin K; Chen W; Tang H
Colloids Surf B Biointerfaces; 2016 Nov; 147():376-386. PubMed ID: 27566226
[TBL] [Abstract][Full Text] [Related]
20. Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design.
Jojo GM; Kuppusamy G; De A; Karri VVSNR
Drug Dev Ind Pharm; 2019 Jul; 45(7):1061-1072. PubMed ID: 30922126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
